Abstract | INTRODUCTION: AREAS COVERED: In this article, the clinical development of pazopanib as it relates to breast cancer is reviewed including its evaluation in clinical trials and side effect profile. Preclinical data show the anti- tumor activity of pazopanib in animal models. Several trials of pazopanib monotherapy and combination therapy in breast cancer have been completed or are underway. EXPERT OPINION: The development of biomarkers predictive of response and toxicity to angiogenesis inhibitors remains a challenging endeavor and is necessary to help guide treatment decision.
|
Authors | Laleh Amiri-Kordestani, Antoinette R Tan, Sandra M Swain |
Journal | Expert opinion on investigational drugs
(Expert Opin Investig Drugs)
Vol. 21
Issue 2
Pg. 217-25
(Feb 2012)
ISSN: 1744-7658 [Electronic] England |
PMID | 22233389
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Review)
|
Chemical References |
- Angiogenesis Inhibitors
- Biomarkers, Tumor
- Indazoles
- Protein Kinase Inhibitors
- Pyrimidines
- Sulfonamides
- pazopanib
- Protein-Tyrosine Kinases
|
Topics |
- Angiogenesis Inhibitors
(therapeutic use)
- Biomarkers, Tumor
- Breast Neoplasms
(drug therapy, genetics)
- Female
- Humans
- Indazoles
- Protein Kinase Inhibitors
(therapeutic use)
- Protein-Tyrosine Kinases
(antagonists & inhibitors)
- Pyrimidines
(therapeutic use)
- Sulfonamides
(therapeutic use)
|